REGENXBIO Reports Third Quarter 2017 Financial Results and Recent Operational Highlights
November 08, 2017 16:05 ET
|
REGENXBIO Inc.
Completed second cohort dosing in RGX-314 Phase I clinical trial for wet AMDCompleted first cohort dosing in RGX-501 Phase I/II clinical trial for HoFHInterim trial updates to be included in the...
REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2017 Financial Results and Recent Operational Highlights
November 01, 2017 07:00 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Nov. 01, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy...
REGENXBIO to Present at Upcoming Investor Conferences
October 03, 2017 07:00 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Oct. 03, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy...
REGENXBIO Responds to Notification of a Superior Proposal Under Its Merger Agreement With Dimension Therapeutics
October 02, 2017 08:30 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Oct. 02, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX) today announced that Dimension Therapeutics, Inc. (Nasdaq:DMTX) notified REGENXBIO that it has determined that it has...
REGENXBIO Announces Completion of Dosing of First Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
September 20, 2017 07:00 ET
|
REGENXBIO Inc.
Six patients dosed at leading retinal surgery centers in the United StatesAll participating study centers now active; next dose cohort is projected to start after review by the Data Safety Monitoring...
REGENXBIO to Present at Upcoming Investor Conferences
August 31, 2017 07:00 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Aug. 31, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene...
REGENXBIO to Acquire Dimension Therapeutics
August 25, 2017 08:00 ET
|
REGENXBIO Inc.
Acquisition will add two lead product candidates to REGENXBIO’s metabolic disease franchise: - DTX301 for OTC deficiency, being studied in an on-going Phase I/II clinical trial - DTX401 for...
REGENXBIO to Present on RGX-314 Gene Therapy Program for Wet AMD at 35th Annual Scientific Meeting of the American Society of Retina Specialists
August 11, 2017 18:13 ET
|
REGENXBIO Inc.
RGX-314 trial design and subretinal delivery overview to be presentedEnrollment continues in RGX-314 Phase I clinical trial for wet AMD; interim update anticipated by year-end 2017 ROCKVILLE, Md.,...
REGENXBIO Reports Second Quarter 2017 Financial Results and Recent Operational Highlights
August 08, 2017 16:05 ET
|
REGENXBIO Inc.
Enrollment continues in RGX-314 Phase I clinical trial for wet AMD; interim update anticipated by year-end 2017Enrollment continues in RGX-501 Phase I/II clinical trial for HoFH; interim update...
REGENXBIO to Host Conference Call on August 8 to Discuss Second Quarter 2017 Financial Results and Recent Operational Highlights
August 01, 2017 16:05 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Aug. 01, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy...